The completed phase I and II clinical trials with E-selectin inhibitor (GMI-1271) in DVT patients have shown high efficiency without clinically significant differences in coagulation measures in comparison with a low-molecular-weight heparin [37, 38]. The gene discussed is SELE; the disease is deep vein thrombosis.